SCHEMBL6669375

SCHEMBL6669375

Oc1c[c]ccc1-c1ccc(F)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.35
PTGS1 P23219 4/20 0.34
PTGS2 P35354 3/20 0.34
ERCC1 P07992 2/20 0.34
ERCC4 Q92889 2/20 0.34
RPS6KA3 P51812 2/20 0.33
BCL2L1 Q07817 2/20 0.32
BAD Q92934 1/20 0.32
GPR35 Q9HC97 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
KDM4E B2RXH2 1/20 0.32
GLA P06280 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
MIF P14174 1/20 0.32
RAB9A P51151 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27688204 0.84 PIK3CA (0.38) PIK3CAPTGS1PTGS2ERCC1ERCC4
SCHEMBL16719637 0.83 ESR1 (0.42) RPS6KA3BCL2L1MEN1KMT2AALDH1A1
SCHEMBL9988102 0.80 BACE1 (0.38) PTGS1PTGS2RPS6KA3BCL2L1MEN1
SCHEMBL16720203 0.80 ALOX5 (0.41) PIK3CAPTGS1PTGS2MEN1KMT2A
SCHEMBL16719460 0.79 KIF11 (0.47) PIK3CAALDH1A1KDM4EPOLBHSD17B10
SCHEMBL16719824 0.79 ESR2 (0.43) KDM4EHSD17B10
SCHEMBL159940 0.79 ALDH1A1 (0.54) BCL2L1MEN1KMT2AALDH1A1HPGD
SCHEMBL150097 0.79 PTGS2 (0.35) PTGS1PTGS2RPS6KA3RAB9ANPC1
SCHEMBL16720371 0.78 CA12 (0.34) PTGS1BCL2L1ALDH1A1HPGDCA6
SCHEMBL16719523 0.78 HSD17B1 (0.40) PIK3CAGAACA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2397462-A2 Compounds, compositions and methods of treatment for heart failure Cytokinetics, Inc. (US) 2011-12-21 EP claimed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 WO disclosed
EP-1153014-B1 BETA-ALANINE DERIVATIVES MERCK PATENT GMBH (DE) 2004-09-22 EP disclosed
US-6576637-B1 Such as 3-(4-methyl-3-nitrophenyl)-3-(2-(4-(pyridin-2-yl-amino)butyryl amino)acetylamino)propionic acid; thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, MERCK PATENT GMBH (DE) 2003-06-10 US disclosed
EP-1153014-A2 BETA-ALANINE DERIVATIVES MERCK PATENT GmbH (DE) 2001-11-14 EP disclosed
WO-2000048996-A2 β-ALANINE DERIVATIVES MERCK PATENT GMBH (DE) 2000-08-24 WO disclosed
US-5120848-A Anticholesterol and antilipemic agents; hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitors GLAXO GROUP LIMITED (GB) 1992-06-09 US disclosed
US-5013749-A Imidazole derivatives and their use as hypercholesterolemia and hyperlipoproteinemia agents GLAXO GROUP LIMITED (GB) 1991-05-07 US disclosed